The BioInnovation Institute Foundation (BII) is an international non-profit foundation supported by the Novo Nordisk Foundation. BII operates an incubator to accelerate world-class life science innovation that drives the development of new solutions by early-stage life science start-ups for the benefit of people and society.
Our vision is to support world-class life science innovation that drives development of new solutions by early life science start-ups for the benefit of people and society.
“BII is the perfect platform for start-up companies in the life science field. During my +20 years in the industry I have founded and co-founded 6 companies, but I have never before had the level of support offered by BII. It’s not only access to seed capital, highly professional guidance in writing a business plan, and an outstanding global network for attracting funding; BII also offers office and lab facilities, legal advice, support with accounting and top-notch gourmet coffee.”
“Becoming part of BioInnovation Institute has made a really big difference. They have managed to build a bridge that has lacked between research and venture capital. It has helped us attract talented people and put in place a solid plan that we are now executing, so we can create a new paradigm in contraception.”
“It has been an amazing experience to participate in the BAA program at BII. We have improved our company’s pitch deck, our business language, and our commercial strategy, which gave us clear advantages in our current fundraising round. We are at a very exciting point in our story and can’t wait to see what the future holds.”
“Our experiences and learnings from BII are less technical in nature, but rather denote the importance of community and (physical) proximity to innovators and facilitators. The BII provides us a world-class workspace to work from, where ideas and experiences are easily shared amongst like-minded entrepreneurs and industry experienced BII staff members. In our particular case, we are flanked by a number of CNS focused therapeutics companies that are all pretty much at the same stage of development. Hence, domain expertise, talent, experience, and support are always just meters away. This has helped us avoid reinventing the wheel many times over. Kariya is on the verge of initiating our regulatory toxicology studies, which is the final preclinical hurdle before going into human studies. “
“Being a part of the BII creation house program has enabled STipe to recruit scientists with the diverse skills that have been essential for the further development of our leading technology for immune-oncology. While the BII team itself has helped us to establish and build relationships within the local and global biotech communities, culminating in a successful Series A round last October. Thanks to the BII we remain on track to deliver a first clinical candidate.”
“There have been many eye openers through the BAA program. We have learned that to bring this to larger patient groups, we will need to show investors that they can make money. We have great science and we have done a great job of getting into the clinic, but we have to present a business case to get the attention of investors. On a different note, we are very grateful and amazed by how involved the team at BioInnovation Institute is with our company’s progression. We expected lectures and tools, but we did not expect the team to put themselves and all of their energy into us. That is such a good experience.”
BioInnovation Institute (BII) supports entrepreneurial researchers and early-stage life science start-ups with up to 18M DKK in founder-friendly funding opportunities, business acceleration and incubation programs, international networks and a vibrant community with access to state-of-the-art labs and office space.
Meet the BII team here or visit our program overview to read more and apply for one of the BII programs.